Our vision is to make the innovative antibiotic susceptibility test (AST) of epsilonDx GmbH the global reference standard for truly personalized antibiotic therapy. We want every patient, wherever they are treated, to receive the most effective antibiotic quickly, safely, and with minimal impact on future resistance.
By enabling same-day, evidence-based treatment decisions, we strive to transform how infectious diseases are managed worldwide – reducing treatment failures and mortality, lowering healthcare costs, and safeguarding the power of antibiotics for future generations.